MA40706A1 - Pyrrolopyrimidines et pyrazolopyrimidines utilisées en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine 7 - Google Patents
Pyrrolopyrimidines et pyrazolopyrimidines utilisées en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine 7Info
- Publication number
- MA40706A1 MA40706A1 MA40706A MA40706A MA40706A1 MA 40706 A1 MA40706 A1 MA 40706A1 MA 40706 A MA40706 A MA 40706A MA 40706 A MA40706 A MA 40706A MA 40706 A1 MA40706 A1 MA 40706A1
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitors
- pyrrolopyrimidines
- pyrazolopyrimidines
- ubiquitin
- diseases
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 title 1
- 102000018390 Ubiquitin-Specific Proteases Human genes 0.000 title 1
- 108010066496 Ubiquitin-Specific Proteases Proteins 0.000 title 1
- 150000004944 pyrrolopyrimidines Chemical class 0.000 title 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 2
- 101100208731 Caenorhabditis elegans math-33 gene Proteins 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000023589 ischemic disease Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'invention concerne des inhibiteurs d'usp7 utiles dans le traitement de cancers, maladies neurodégénératives, troubles immunologiques, troubles inflammatoires, maladies cardiovasculaires, maladies ischémiques, maladies et infections virales, et maladies et infections bactériennes, lesdits inhibiteurs étant représentés par la formule : (i) dans laquelle m, n, x
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462098141P | 2014-12-30 | 2014-12-30 | |
| PCT/US2015/067831 WO2016109515A1 (fr) | 2014-12-30 | 2015-12-29 | Pyrrolopyrimidines et pyrazolopyrimidines utilisées en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine 7 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA40706A1 true MA40706A1 (fr) | 2018-02-28 |
Family
ID=55310894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA40706A MA40706A1 (fr) | 2014-12-30 | 2015-12-29 | Pyrrolopyrimidines et pyrazolopyrimidines utilisées en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine 7 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9902728B2 (fr) |
| EP (2) | EP3623372B1 (fr) |
| JP (1) | JP6649388B2 (fr) |
| KR (1) | KR102581827B1 (fr) |
| CN (1) | CN107406451B (fr) |
| AR (1) | AR103297A1 (fr) |
| AU (2) | AU2015374170B2 (fr) |
| CA (1) | CA2972797C (fr) |
| CL (1) | CL2017001687A1 (fr) |
| CO (1) | CO2017006997A2 (fr) |
| EA (1) | EA038204B1 (fr) |
| EC (1) | ECSP17049010A (fr) |
| ES (2) | ES2768996T3 (fr) |
| IL (1) | IL252773A0 (fr) |
| MA (1) | MA40706A1 (fr) |
| MX (2) | MX373788B (fr) |
| PH (1) | PH12017501224A1 (fr) |
| SA (1) | SA517381839B1 (fr) |
| SG (1) | SG11201704897QA (fr) |
| TW (2) | TWI698436B (fr) |
| WO (1) | WO2016109515A1 (fr) |
| ZA (1) | ZA201704746B (fr) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX389479B (es) | 2011-09-02 | 2025-03-20 | Incyte Holdings Corp | Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k) |
| US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| EP3200589B1 (fr) | 2014-09-10 | 2026-03-11 | Temple University Of The Commonwealth System Of Higher Education | Nouveaux modulateurs de l'activité du récepteur de 5-hydroxytryptamine 7 et leur procédé d'utilisation |
| MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
| TWI698436B (zh) | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶 |
| EP3253765A1 (fr) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Thiénopyrimidinones utilisées comme inhibiteurs de la protéase 7 spécifique de l'ubiquitine |
| EP3253738A1 (fr) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Quinazolinones et azaquinazolinones comme inhibiteurs de la protéase 7 spécifique de l'ubiquitine |
| HK1248221A1 (zh) | 2015-02-05 | 2018-10-12 | Forma Therapeutics, Inc. | 异噻唑啉酮类,吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂 |
| SG10201912302VA (en) | 2015-02-27 | 2020-02-27 | Incyte Corp | Salts of pi3k inhibitor and processes for their preparation |
| CN108884077A (zh) * | 2016-02-25 | 2018-11-23 | 阿森纽荣股份公司 | 糖苷酶抑制剂 |
| WO2017201683A1 (fr) | 2016-05-25 | 2017-11-30 | Merck Sharp & Dohme Corp. | Composés de tétrahydroisoquinoline substitués utiles à titre d'agonistes de gpr120 |
| PL3468971T3 (pl) | 2016-06-10 | 2020-08-10 | Les Laboratoires Servier | Nowe pochodne (hetero)arylo-piperydynylowe, sposoby ich wytwarzania oraz zawierające je kompozycje |
| FR3052452B1 (fr) * | 2016-06-10 | 2018-06-22 | Les Laboratoires Servier | Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3061177B1 (fr) * | 2016-12-28 | 2019-09-27 | Les Laboratoires Servier | Nouveaux derives piperidinyles hetero(aryle)-substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
| EP3481803B1 (fr) | 2016-07-08 | 2020-09-02 | Mayo Foundation for Medical Education and Research | Procédés et matériaux de traitement du cancer |
| GB201612938D0 (en) * | 2016-07-26 | 2016-09-07 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB201617758D0 (en) * | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| MX2019004950A (es) | 2016-10-28 | 2019-09-26 | Icahn School Med Mount Sinai | Composiciones y metodos para tratar el cancer mediado por el potenciador del homologo zeste 2. |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| CA3045037A1 (fr) | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions et methodes pour le traitement du cancer a mediation par cdk4/6 |
| CN108239082B (zh) * | 2016-12-26 | 2021-01-05 | 成都先导药物开发股份有限公司 | 一种抑制rock的化合物及其应用 |
| JP7365237B2 (ja) | 2017-03-21 | 2023-10-19 | テンプル・ユニバーシティ-オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | シグマ-2受容体の新規調節物質およびその使用方法 |
| EP3600289A4 (fr) | 2017-03-21 | 2020-08-05 | Temple University - Of The Commonwealth System of Higher Education | Modulateurs du récepteur 7 de la 5-hydroxytryptamine et utilisation de ces derniers en tant qu'agents thérapeutiques |
| MY202326A (en) | 2017-09-14 | 2024-04-24 | Daiichi Sankyo Co Ltd | Compound having cyclic structure |
| AU2018342089B2 (en) | 2017-09-26 | 2024-07-11 | Dana-Farber Cancer Institute, Inc. | Novel USP7 inhibitors for treating multiple myeloma |
| WO2019084026A1 (fr) | 2017-10-24 | 2019-05-02 | Genentech, Inc. | Composés (4-hydroxypyrrolidin-2-yl)-hétérocycliques et leurs procédés d'utilisation |
| WO2019084030A1 (fr) | 2017-10-24 | 2019-05-02 | Genentech, Inc. | Composés de (4-hydroxypyrrolidin-2-yl)-hydroxamate et leurs procédés d'utilisation |
| TW201925202A (zh) | 2017-11-29 | 2019-07-01 | 法商施維雅藥廠 | 新穎哌啶基衍生物、其製備方法及含其之醫藥組合物 |
| IL275059B2 (en) | 2017-12-15 | 2023-11-01 | Pyramid Biosciences Inc | 5-(2-(5,2-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[5,1-A]pyrimidine derivatives and related compounds as TRK kinase inhibitors for cancer therapy |
| BR112020012651A2 (pt) * | 2017-12-22 | 2020-12-01 | Ravenna Pharmaceuticals, Inc. | compostos derivados de aril-bipiridina amina como inibidores da fosfatidilinositol fosfato quinase, composição farmacêutica compreendendo os mesmos e usos terapêuticos dos ditos compostos |
| GB201801562D0 (en) | 2018-01-31 | 2018-03-14 | Almac Diagnostics Ltd | Pharmaceutical compounds |
| JP2021515013A (ja) | 2018-03-06 | 2021-06-17 | アイカーン スクール オブ メディスン アット マウント シナイ | セリンスレオニンキナーゼ(akt)分解/破壊化合物および使用方法 |
| WO2019183523A1 (fr) | 2018-03-23 | 2019-09-26 | Genentech, Inc. | Composés de dégradation hétéro-bifonctionnels et leur utilisation en tant que modulateurs de l'ubiquination ciblée (vhl) |
| WO2019189731A1 (fr) | 2018-03-30 | 2019-10-03 | 住友化学株式会社 | Composé hétérocyclique et agent de lutte contre les arthropodes nuisibles le contenant |
| US12539292B2 (en) | 2018-04-01 | 2026-02-03 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| JP7349450B2 (ja) | 2018-04-25 | 2023-09-22 | バイエル・アクチエンゲゼルシヤフト | 殺有害生物剤としての新規ヘテロアリール-トリアゾール化合物及びヘテロアリール-テトラゾール化合物 |
| JP2021527666A (ja) | 2018-06-21 | 2021-10-14 | アイカーン スクール オブ メディスン アット マウント シナイ | Wd40反復ドメインタンパク質5(wdr5)分解/破壊化合物および使用の方法 |
| UY38291A (es) * | 2018-07-05 | 2020-06-30 | Servier Lab | Nuevos derivados de amino-pirimidonilo un proceso para su preparación y composiciones farmacéuticas |
| WO2020010204A1 (fr) | 2018-07-05 | 2020-01-09 | Icahn School Of Medicine At Mount Sinai | Composés de dégradation/perturbation de la protéine tyrosine kinase 6 (ptk6) et méthodes d'utilisation |
| EP3870179A4 (fr) | 2018-10-22 | 2022-11-23 | Dana Farber Cancer Institute, Inc. | Inhibition d'usp7 |
| KR102712818B1 (ko) | 2018-12-06 | 2024-09-30 | 한국화학연구원 | Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도 |
| US20220033397A1 (en) * | 2018-12-06 | 2022-02-03 | Almac Discovery Limited | Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19) |
| JP2022510700A (ja) * | 2018-12-06 | 2022-01-27 | アルマック・ディスカバリー・リミテッド | 治療において使用するusp19阻害剤 |
| CN109666005A (zh) * | 2018-12-14 | 2019-04-23 | 上海毕得医药科技有限公司 | 一种2-溴恶唑-5-甲酸乙酯的合成方法 |
| WO2020142557A1 (fr) | 2018-12-31 | 2020-07-09 | Biomea Fusion, Llc | Inhibiteurs irréversibles de l'interaction ménine-mll |
| TW202043205A (zh) | 2018-12-31 | 2020-12-01 | 美商拜歐米富士恩有限公司 | Menin-mll相互作用之抑制劑 |
| US12479816B2 (en) | 2019-02-08 | 2025-11-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | 20-HETE formation inhibitors |
| EP3923987A1 (fr) | 2019-02-14 | 2021-12-22 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Utilisation d'inhibiteurs de l'usp7 pour le traitement de la leucémie aiguë myéloïde (lam) |
| CN109912598B (zh) * | 2019-03-27 | 2022-09-13 | 四川大学华西医院 | 防治炎症反应的核苷类衍生物及其应用 |
| CN113423709B (zh) * | 2019-04-11 | 2024-02-09 | 四川科伦博泰生物医药股份有限公司 | 三嗪酮并咪唑类化合物及其医药用途 |
| CN114423463B (zh) | 2019-05-06 | 2025-09-26 | 西奈山伊坎医学院 | 作为hpk1的降解剂的异双功能化合物 |
| CN112608320B (zh) * | 2020-01-16 | 2023-03-17 | 中国药科大学 | 哌啶类化合物及其制备方法和医药用途 |
| GB202001980D0 (en) | 2020-02-13 | 2020-04-01 | Almac Discovery Ltd | Therapeutic mentods |
| IL296921B1 (en) | 2020-04-15 | 2026-08-01 | Pyramid Biosciences Inc | Methods for preparing receptor tyrosine kinase inhibitors |
| JP7626347B2 (ja) | 2020-04-27 | 2025-02-04 | オートタック インコーポレーテッド | Ubrボックスドメインリガンドとしての化合物 |
| US12103924B2 (en) | 2020-06-01 | 2024-10-01 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use |
| UY39391A (es) * | 2020-08-24 | 2022-03-31 | Adama Makhteshim Ltd | Proceso para la preparación de pirazoles sustituidos |
| WO2022159650A1 (fr) * | 2021-01-22 | 2022-07-28 | Icahn School Of Medicine At Mount Sinai | Composés hétérobifonctionnels utilisés en tant qu'agents de dégradation de l'eef1a2 |
| IL305262A (en) | 2021-03-10 | 2023-10-01 | Jnana Therapeutics Inc | Small molecule inhibitors of mammalian SLC6A19 function |
| CN117412973B (zh) * | 2021-05-31 | 2026-07-17 | 上海瑛派药业有限公司 | 含氮稠合杂芳双环化合物作为usp1抑制剂及其应用 |
| WO2023004291A1 (fr) * | 2021-07-19 | 2023-01-26 | Baylor College Of Medicine | Inhibiteurs de protéase principale du coronavirus et leurs méthodes d'utilisation |
| JP2024526849A (ja) * | 2021-07-20 | 2024-07-19 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | ユビキチン特異的プロテアーゼ7(usp7)を標的とする阻害剤 |
| JP7891524B2 (ja) | 2021-08-11 | 2026-07-16 | バイオメア フュージョン,インコーポレイテッド | 真性糖尿病に対するメニン-mll相互作用の共有結合性阻害剤 |
| MX2024002189A (es) | 2021-08-20 | 2024-06-11 | Biomea Fusion Inc | Forma cristalina de n-[4-[4-(4-morfolinil)-7h-pirrolo[2,3-d]pirimi din-6-il]fenil]-4-[[3(r)-[(1-oxo)-2-propen-1-il)amino]-1-piperidi nil]metil]-2-piridinacarboxamida, un inhibidor irreversible de menina-mll para el tratamiento del cancer. |
| GB202200753D0 (en) * | 2022-01-21 | 2022-03-09 | Almac Discovery Ltd | Pharmaceutical compounds |
| CN114957248B (zh) * | 2022-05-09 | 2023-12-29 | 南开大学 | 一种吡咯并嘧啶化合物及其制备方法、药物组合物和应用 |
| WO2024155719A1 (fr) | 2023-01-18 | 2024-07-25 | Biomea Fusion, Inc. | Formes cristallines de n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phényl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-pipéridinyl]méthyl]-2- pyridinecarboxamide en tant qu'inhibiteur covalent de l'interaction ménine-mll |
| EP4467535A1 (fr) | 2023-05-25 | 2024-11-27 | Basf Se | Composés pesticides à base de lactame |
| CN121219276A (zh) | 2023-05-25 | 2025-12-26 | 巴斯夫欧洲公司 | 内酰胺杀有害生物化合物 |
| KR20260049549A (ko) * | 2023-08-11 | 2026-04-14 | 제이나나 테라퓨틱스 인코포레이티드 | Slc6a19 기능의 바이사이클릭 헤테로아릴 함유 피페리딘 억제제 |
| CN118496138B (zh) * | 2024-07-10 | 2024-12-03 | 西北农林科技大学深圳研究院 | 一种l-氮杂环丁烷-2-羧酸的合成方法 |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5985863A (en) | 1996-09-12 | 1999-11-16 | Vertex Pharmaceuticals, Inc. | Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor |
| US5874424A (en) | 1995-12-20 | 1999-02-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US6204261B1 (en) | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
| US6008217A (en) | 1995-12-20 | 1999-12-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| IN151496B (fr) | 1980-02-26 | 1983-05-07 | Chamanlal Jagannath Shishoo | |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| JP2777159B2 (ja) | 1988-12-22 | 1998-07-16 | エーザイ株式会社 | 環状アミン誘導体を含有する医薬 |
| US5124335A (en) | 1991-01-30 | 1992-06-23 | Merck & Co., Inc. | Substituted pyrollo-fused 6 membered heterocycles as angiotensin ii antagonists |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| US5716929A (en) | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US6420522B1 (en) | 1995-06-05 | 2002-07-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US5847135A (en) | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US5756466A (en) | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US20120165319A1 (en) | 1995-12-20 | 2012-06-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1 beta converting enzyme |
| FR2750862B1 (fr) | 1996-07-12 | 1998-10-16 | Dupin Jean Pierre | Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques |
| CA2288735A1 (fr) | 1997-05-08 | 1998-11-12 | Agrevo Uk Limited | Fongicides |
| US6444816B1 (en) | 1997-10-27 | 2002-09-03 | Dr. Reddy's Research Foundation | Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof |
| CN1208326C (zh) | 1998-04-23 | 2005-06-29 | 雷迪实验室有限公司 | 杂环化合物及其在医药方面的应用、其制备方法及含有它们的药物组合物 |
| US6844367B1 (en) | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| US6720317B1 (en) | 1999-09-17 | 2004-04-13 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| US20060183776A9 (en) | 2000-03-03 | 2006-08-17 | Eisai Co., Ltd. | Liquid dosage formulations of donepezil |
| US20030153598A1 (en) | 2000-07-25 | 2003-08-14 | Raymond Pratt | Methods for treating Parkinson's disease with cholinesterase inhibitors |
| DE60124730T2 (de) | 2000-03-03 | 2007-10-04 | Eisai R&D Management Co., Ltd. | Neue methoden unter verwendung von cholinesteraseinhibitoren |
| CA2411013A1 (fr) | 2000-06-07 | 2001-12-13 | Jose Manuel Prieto Soto | Derives de 6-phenyl-pyrrolo-pyrimidine |
| AU2001268712A1 (en) | 2000-06-23 | 2002-01-08 | Bristol-Myers Squibb Company | 1 - (heteroaryl-phenyl) - condensed pyrazol derivatives as factor Xa inhibitors |
| JP2002105081A (ja) | 2000-07-28 | 2002-04-10 | Nikken Chem Co Ltd | 新規チオフェンニ環化合物 |
| PE20020394A1 (es) * | 2000-08-18 | 2002-06-21 | Agouron Pharma | Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2 |
| US20020169175A1 (en) | 2001-02-05 | 2002-11-14 | Dr. Reddy's Laboratories Ltd. | Pharmaceutically acceptable salts of heterocyclic compounds |
| US6960595B2 (en) | 2001-03-23 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | 5-6 to 5-7 Heterobicycles as factor Xa inhibitors |
| WO2003024456A1 (fr) | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methodes de traitement et de prevention des migraines |
| AU2002340232A1 (en) | 2001-10-17 | 2003-04-28 | Eisai Co., Ltd. | Methods for treating substance abuse with cholinesterase inhibitors |
| CA2476583C (fr) | 2002-03-13 | 2011-07-05 | Kristof Van Emelen | Derives aminocarbonyl utilises en tant que nouveaux inhibiteurs d'histone deacetylase |
| WO2003092606A2 (fr) | 2002-05-01 | 2003-11-13 | Eisai Co., Ltd. | Inhibiteurs de cholinesterase pour prevenir les blessures causees par des produits chimiques |
| US20070053976A1 (en) | 2002-05-17 | 2007-03-08 | Eisai R & D Management Co., Ltd. | Novel combination of drugs as antidepressant |
| WO2004034963A2 (fr) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methodes et compositions utilisant des inhibiteurs de la cholinesterase |
| AU2003249477A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Heterobicylcic metalloproteinase inhibitors |
| AU2003253165A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| WO2004037176A2 (fr) * | 2002-10-21 | 2004-05-06 | Bristol-Myers Squibb Company | Quinazolinones et derives de celles-ci comme inhibiteurs du facteur xa |
| WO2004058727A1 (fr) | 2002-12-20 | 2004-07-15 | Bayer Pharmaceuticals Corporation | 3,5-dihydro-4-h-imidazol-4-ones substitues utilises dans le traitement de l'obesite |
| ATE368666T1 (de) | 2003-03-18 | 2007-08-15 | Jordanian Pharmaceutical Mfg | Pyrazolopyrimidinone und ihre verwendung als pde inhibitoren |
| ATE440825T1 (de) | 2003-06-06 | 2009-09-15 | Vertex Pharma | Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern |
| CN1871240B (zh) | 2003-08-26 | 2012-11-07 | 帝人制药株式会社 | 吡咯并嘧啶酮衍生物 |
| US7557113B2 (en) | 2003-08-26 | 2009-07-07 | Teijin Pharma Limited | Substituted pyrrolo[3,2-d]pyrimidine derivatives |
| US20050187147A1 (en) | 2003-09-22 | 2005-08-25 | Newman Michael J. | Compositions and methods for increasing drug efficiency |
| US20050148534A1 (en) | 2003-09-22 | 2005-07-07 | Castellino Angelo J. | Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
| AU2004276337B2 (en) | 2003-09-24 | 2009-11-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US20080312189A1 (en) | 2004-03-05 | 2008-12-18 | Eisai Co., Ltd. | Cadasil Treatment with Cholinesterase Inhibitors |
| US7253204B2 (en) | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
| DK1737831T3 (da) | 2004-04-02 | 2013-08-19 | Prana Biotechnology Ltd | Neurologisk aktive forbindelser |
| EP1779867A4 (fr) | 2004-07-01 | 2009-12-02 | Eisai R&D Man Co Ltd | Promoteur de la régénérescence nerveuse |
| US20060172992A1 (en) | 2004-08-13 | 2006-08-03 | Eisai Co., Ltd. | Therapeutic agent for overactive bladder resulting from cerebral infarction |
| US20060135507A1 (en) | 2004-08-13 | 2006-06-22 | Osamu Yokoyama | Therapeutic agent for overactive bladder involved in aging |
| US20090118261A1 (en) | 2004-08-31 | 2009-05-07 | Astrazeneca Ab | Quinazolinone derivatives and their use as b-raf inhibitors |
| US20080064680A1 (en) | 2004-09-14 | 2008-03-13 | Bamdad Cynthia C | Methods for Diagnosis and Treatment of Cancer |
| JP2006176503A (ja) | 2004-11-26 | 2006-07-06 | Tohoku Univ | 脳血管障害を伴うアルツハイマー病治療薬 |
| KR20070090206A (ko) | 2004-12-24 | 2007-09-05 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 2환식 피롤 유도체 |
| EP1876179B1 (fr) | 2005-04-28 | 2015-03-25 | Takeda Pharmaceutical Company Limited | Composés de thiénopyrimidone |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| US7745447B2 (en) | 2005-10-26 | 2010-06-29 | Bristol-Myers Squibb Company | Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists |
| US8618115B2 (en) | 2005-10-26 | 2013-12-31 | Bristol-Myers Squibb Company | Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them |
| CN101384594A (zh) | 2005-12-23 | 2009-03-11 | 诺瓦提斯公司 | 用作dpp-iv抑制剂的稠合杂环化合物 |
| US20080119457A1 (en) | 2006-08-24 | 2008-05-22 | Serenex, Inc. | Benzene, Pyridine, and Pyridazine Derivatives |
| WO2008094909A2 (fr) | 2007-01-29 | 2008-08-07 | Xenon Pharmaceuticals Inc. | Composés de quinazolinone et de pyrimidinone fusionnés et leur utilisation dans le traitement de maladies ou d'affections induites par les canaux sodiques |
| EP2073799A4 (fr) | 2007-03-12 | 2009-08-19 | Vm Discovery Inc | Nouveaux agents modulateurs des canaux d'ions calcium |
| CN103087043A (zh) | 2007-03-16 | 2013-05-08 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 具有抗增殖活性的苯甲酰胺类衍生物及其药用制剂 |
| US20100184706A1 (en) * | 2007-03-20 | 2010-07-22 | Bachovchin William W | Fap-activated chemotherapeutic compounds, and methods of use thereof |
| WO2008138126A1 (fr) | 2007-05-09 | 2008-11-20 | Neuromed Pharmaceuticals Ltd. | Dérivés bicycliques de pyrimidine en tant que bloqueurs des canaux calciques |
| RU2345996C1 (ru) | 2007-07-17 | 2009-02-10 | Андрей Александрович Иващенко | Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения |
| RU2341527C1 (ru) | 2007-07-17 | 2008-12-20 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Аннелированные азагетероциклы, включающие пиримидиновый фрагмент, способ их получения и ингибиторы pi3k киназ |
| US8648085B2 (en) * | 2007-11-30 | 2014-02-11 | Boehringer Ingelheim International Gmbh | 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders |
| UA105362C2 (en) * | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| CA2719362A1 (fr) | 2008-04-04 | 2009-10-08 | Gilead Sciences, Inc. | Derives de pyrrolotriazinone pouvant etre utilises a titre d'inhibiteurs de stearoyl-coa desaturase |
| CA2737219C (fr) | 2008-08-11 | 2017-02-28 | Tracy Keller | Analogues d'halofuginone pour l'inhibition d'arnt synthetases et leurs utilisations |
| US20110082158A1 (en) | 2008-10-01 | 2011-04-07 | Aleem Gangjee | Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same |
| WO2010075561A1 (fr) | 2008-12-23 | 2010-07-01 | President And Fellows Of Harvard College | Inhibiteurs de la nécroptose de petite taille moléculaire |
| BRPI1009398A2 (pt) | 2009-03-13 | 2016-03-08 | Advinus Therapeutics Private Ltd | compostos de pirimidina fundida substituída |
| US8927718B2 (en) | 2009-08-26 | 2015-01-06 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring derivative and use thereof |
| CN102666540A (zh) | 2009-10-13 | 2012-09-12 | Msd欧斯股份有限公司 | 用于治疗乙酰胆碱受体相关疾病的稠合吖嗪衍生物 |
| WO2011097607A1 (fr) | 2010-02-08 | 2011-08-11 | Southern Research Institute | Traitement antiviral et dosage pour cribler des antiviraux |
| US8575114B2 (en) | 2010-03-23 | 2013-11-05 | Albany Molecular Research, Inc. | SGLT-2 inhibitors, methods of making them, and uses thereof |
| WO2012054332A1 (fr) | 2010-10-18 | 2012-04-26 | Millennium Pharmaceuticals, Inc. | Acides hydroxamiques substitués et leurs utilisations |
| WO2012075393A2 (fr) | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activateurs de la dégradation protéasomique et leurs utilisations |
| JP2014515345A (ja) * | 2011-01-10 | 2014-06-30 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 脂肪酸シンターゼ阻害剤としてのピリミジノン誘導体 |
| GB201107768D0 (en) | 2011-05-10 | 2011-06-22 | Univ Manchester | Riboswitches |
| EP2565186A1 (fr) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Inhibiteurs sélectifs et réversibles de la protéase 7 spécifique de l'ubiquitine |
| US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
| WO2013130660A1 (fr) | 2012-02-28 | 2013-09-06 | Amgen Inc. | Amides convenant comme inhibiteurs des pim |
| GB201205164D0 (en) | 2012-03-23 | 2012-05-09 | Almac Discovery Ltd | Pharmaceutical compounds |
| EP2938610A2 (fr) | 2012-12-28 | 2015-11-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Inhibiteurs du complexe usp1/uaf1 désubiquitinase et leurs utilisations |
| KR101446680B1 (ko) | 2013-02-08 | 2014-10-07 | 한국과학기술연구원 | mGluR1 길항제로 작용하는 사이에노피리미디논 유도체 |
| CN103833646A (zh) | 2014-02-28 | 2014-06-04 | 广东工业大学 | 一种脂肪氨基取代喹唑啉酮衍生物及其制备方法和应用 |
| TWI698436B (zh) | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶 |
| MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
| HK1248221A1 (zh) | 2015-02-05 | 2018-10-12 | Forma Therapeutics, Inc. | 异噻唑啉酮类,吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂 |
| EP3253765A1 (fr) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Thiénopyrimidinones utilisées comme inhibiteurs de la protéase 7 spécifique de l'ubiquitine |
| EP3253738A1 (fr) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Quinazolinones et azaquinazolinones comme inhibiteurs de la protéase 7 spécifique de l'ubiquitine |
-
2015
- 2015-12-28 TW TW104144096A patent/TWI698436B/zh active
- 2015-12-28 TW TW109118957A patent/TWI770525B/zh active
- 2015-12-28 AR ARP150104312A patent/AR103297A1/es unknown
- 2015-12-29 CA CA2972797A patent/CA2972797C/fr active Active
- 2015-12-29 AU AU2015374170A patent/AU2015374170B2/en active Active
- 2015-12-29 MX MX2017008604A patent/MX373788B/es active IP Right Grant
- 2015-12-29 CN CN201580077002.3A patent/CN107406451B/zh active Active
- 2015-12-29 WO PCT/US2015/067831 patent/WO2016109515A1/fr not_active Ceased
- 2015-12-29 EP EP19207235.3A patent/EP3623372B1/fr active Active
- 2015-12-29 US US14/982,127 patent/US9902728B2/en active Active
- 2015-12-29 ES ES15832772T patent/ES2768996T3/es active Active
- 2015-12-29 EP EP15832772.6A patent/EP3240791B1/fr active Active
- 2015-12-29 EA EA201791507A patent/EA038204B1/ru unknown
- 2015-12-29 ES ES19207235T patent/ES3064411T3/es active Active
- 2015-12-29 MA MA40706A patent/MA40706A1/fr unknown
- 2015-12-29 SG SG11201704897QA patent/SG11201704897QA/en unknown
- 2015-12-29 JP JP2017535007A patent/JP6649388B2/ja active Active
- 2015-12-29 KR KR1020177021230A patent/KR102581827B1/ko active Active
-
2017
- 2017-06-08 IL IL252773A patent/IL252773A0/en unknown
- 2017-06-23 CL CL2017001687A patent/CL2017001687A1/es unknown
- 2017-06-27 MX MX2020002963A patent/MX2020002963A/es unknown
- 2017-06-29 SA SA517381839A patent/SA517381839B1/ar unknown
- 2017-06-29 PH PH12017501224A patent/PH12017501224A1/en unknown
- 2017-07-12 CO CONC2017/0006997A patent/CO2017006997A2/es unknown
- 2017-07-13 ZA ZA2017/04746A patent/ZA201704746B/en unknown
- 2017-07-28 EC ECIEPI201749010A patent/ECSP17049010A/es unknown
-
2018
- 2018-01-18 US US15/874,163 patent/US10377760B2/en active Active
-
2019
- 2019-07-19 US US16/517,149 patent/US10934299B2/en active Active
-
2021
- 2021-01-20 AU AU2021200346A patent/AU2021200346A1/en not_active Abandoned
- 2021-02-26 US US17/186,915 patent/US12018030B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501224A1 (en) | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | |
| HK1246285A1 (zh) | 作为泛素特异性蛋白酶7(usp7)抑制剂用於治疗癌症的吡咯并三嗪酮和咪唑并三嗪酮衍生物 | |
| HK1248221A1 (zh) | 异噻唑啉酮类,吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂 | |
| MA41013A (fr) | Compositions comprenant des souches bactériennes | |
| HK1248222A1 (zh) | 噻吩并嘧啶酮作为泛素特异性蛋白酶7抑制剂 | |
| MX379543B (es) | Purinonas como inhibidores de proteasa específica de ubiquitina 1. | |
| PH12017500583A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| HK1248220A1 (zh) | 喹唑啉酮和偶氮喹唑啉作为泛特丁胺蛋白酶7抑制剂 | |
| PH12016501457B1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| MX2018005694A (es) | 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas. | |
| MX385332B (es) | Moduladores de ror-gamma. | |
| MX383213B (es) | Inhibidores de tirosina-cinasas | |
| MX2016002238A (es) | Alcoholes de alquilino y metodos de uso. | |
| MX386935B (es) | Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. | |
| WO2016127179A3 (fr) | Agents immunomodulateurs | |
| MX2016002241A (es) | Alcoholes de alquinilo y metodos de uso. | |
| MX382624B (es) | Compuestos farmacéuticos. | |
| UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
| WO2016057413A3 (fr) | Inhibiteurs de lysine gingipaïne | |
| MX2020009566A (es) | Compuestos como moduladores de la se?alizacion de tlr2. | |
| TR201905218T4 (tr) | Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler. | |
| PH12019500535A1 (en) | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | |
| MX2020012065A (es) | Compuestos de ciclopentano. | |
| WO2015198263A3 (fr) | Nouveaux dérivés substitués par proline bétulinique utilisés comme inhibiteurs du vih | |
| PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases |